TORONTO, June 26 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc. today announced the presentation of data that demonstrates the combined clinical effectiveness of its Endotoxin Activity Assay (EAA(TM)), the only FDA cleared diagnostic for the measurement of endotoxin, to identify patients with elevated endotoxin levels and to guide endotoxin reducing strategies, such as Toray Medical’s therapeutic column, Toraymyxin(TM). The presentations will be made at a symposium entitled “Blood Purification in the Treatment of Sepsis,” at the International Shock Congress in Cologne, Germany to be held from June 28-July 2.
“Several of the presentations at this important congress use data collected with Spectral’s EAA(TM) and highlight the value of our product, both independently and in combination with anti-endotoxin therapies,” said Dr. Paul Walker, President and CEO of Spectral. “Increasingly, EAA(TM) and Toray’s therapeutic column, Toraymyxin(TM), which removes endotoxin from the bloodstream, are being recognized as a valuable combination for the diagnosis, treatment and monitoring of patients with severe sepsis.”
The “Blood Purification in the Treatment of Sepsis” symposium will be held on July 1, from 8:30-10:00AM CEST. Speakers presenting data using EAA(TM) include Dr. David Klein of St. Michael’s Hospital in Toronto, Canada, who will deliver a presentation entitled, “The Endotoxin Activity Assay (EAA(TM)) as a diagnostic tool for anti-endotoxin sepsis treatment”. Dr. Eugen Faist of the University of Munich in Germany will speak about, “Endotoxemia and immune profiles of patients with acute sepsis due to major peritonitis”. Information on the meeting, including the full scientific program, can be seen at www.shocksociety.org.
About Spectral Diagnostics
Spectral is a leader in the battle against sepsis. Spectral’s lead product is its Endotoxin Activity Assay (EAA(TM)), the only FDA cleared assay for the measurement of endotoxin. With the growing awareness for the role of endotoxemia in sepsis and the increasing number of therapies being developed for this indication, Spectral is well-positioned to drive the adoption of the EAA(TM), which can be used to identify patients, enable therapeutics and monitor treatment. Spectral is listed on TSX under the symbol SDI.
Forward-looking statement
Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral’s senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.
The TSX has not reviewed and does not accept responsibility for the
adequacy or accuracy of this statement.
CONTACT: Dr. Paul Walker, President & CEO, (416) 626-3233 ex. 2100; James
Smith, Investor Relations, (416) 815-0700 ext. 229, jsmith@equicomgroup.com